



The Question: Should the County's health plan continue to cover anti-obesity GLP-1 medications prescribed **for weight-loss only** without other comorbid presenting conditions such as Type-2 diabetes?

Costs to Plan:

Year	# OF Rx	Rx Increase	Total Spend	\$ Increase
2023	115		\$625,500	
2024	149	↑ 29.6%	\$1,264,000	↑ 102.1%
2025	187	↑ 25.5%	\$1,539,100	↑ 21.9%

20.5%

2025 Share of
total annual Rx
spend

519.6%

Spend Allowed
Over Benchmark

Cost to Employees: (estimated rates)

	Per MONTH									Per YEAR		Per Paycheck	
	2026	2027 w/ GLP-1	% Increase (w/ GLP-1)	EE \$ Up (w/ GLP-1)	ER \$ Up (w/ GLP-1)	2027 No GLP-1	% Increase (No GLP-1)	EE \$ Up (No GLP-1)	ER \$ Up (No GLP-1)	EE \$ Up (w/ GLP-1)	EE \$ Up (No GLP-1)	EE \$ Up (w/ GLP-1)	EE \$ Up (No GLP-1)
single	\$ 913.27	\$ 1,020.08	11.7%	\$ 21.36	\$ 85.45	\$ 965.28	5.7%	\$ 10.40	\$ 41.61	\$ 256.34	\$ 124.82	\$ 9.86	\$ 4.80
dual	\$ 2,191.85	\$ 2,448.19	11.7%	\$ 51.27	\$ 205.07	\$ 2,316.68	5.7%	\$ 24.97	\$ 99.86	\$ 615.22	\$ 299.59	\$ 23.66	\$ 11.52
family	\$ 2,739.81	\$ 3,060.24	11.7%	\$ 64.09	\$ 256.34	\$ 2,895.85	5.7%	\$ 31.21	\$ 124.83	\$ 769.03	\$ 374.50	\$ 29.58	\$ 14.40
hsa-single	\$ 770.48	\$ 857.90	11.3%	\$ 17.48	\$ 69.94	\$ 811.67	5.3%	\$ 8.24	\$ 32.95	\$ 209.81	\$ 98.86	\$ 8.07	\$ 3.80
hsa-dual	\$ 1,849.14	\$ 2,058.96	11.3%	\$ 41.96	\$ 167.86	\$ 1,948.01	5.3%	\$ 19.77	\$ 79.10	\$ 503.57	\$ 237.29	\$ 19.37	\$ 9.13
hsa-family	\$ 2,311.44	\$ 2,573.70	11.3%	\$ 52.45	\$ 209.81	\$ 2,435.01	5.3%	\$ 24.71	\$ 98.86	\$ 629.42	\$ 296.57	\$ 24.21	\$ 11.41
	Per MONTH									Per YEAR		Per Paycheck	

Employee Sentiment:

The County should cover GLP-1 prescriptions solely for weight loss				
Strongly Disagree	Somewhat Disagree	Neither Agree/ Disagree	Somewhat Agree	Strongly Agree
17.94%	13.72%	23.48%	15.30%	29.55%
31.66%			44.85%	

39.95%

Employees who's top
priority is keeping
premiums lower

The **Kalamazoo County Health Care Coalition** recommends the County eliminate coverage of GLP-1 medications when prescribed solely for the treatment of obesity or weight management, while preserving coverage of GLP-1 medications prescribed for other medically accepted indications, including but not limited to the treatment of Type 2 diabetes or other conditions for which the medication is approved and determined to be medically necessary in accordance with the terms of the health plan.